City Therapeutics, an RNAi startup founded by former Alnylam executives, raised $99.5 million to accelerate clinical development of its first three RNAi candidates and expand beyond liver-focused targets. The funding underscores investor appetite for antibody-like differentiation in RNA interference, with the company aiming to deepen target coverage as it moves candidates toward human proof-of-concept.